iCAD To Present Positive Four-Year Data On Xoft® Axxent® Electronic Brachytherapy (eBx®) System® For Non-Melanoma Skin Cancer (NMSC)

Introduces Comprehensive Solution for the Xoft System for Busy Clinical Practices

NASHUA, N.H. and SAN FRANCISCO, C.A. (Booth # 5151) (March 20, 2015) – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that researchers will present three E- posters highlighting results of up to four years of follow up with the Xoft Axxent® Electronic Brachytherapy (eBx®) System® in the treatment of non-melanoma skin cancer (NMSC) at The American Academy of Dermatology 73rd Annual Meeting in San Francisco, California. The Xoft System’s suite of products and services for clinical practices will also be showcased at the Xoft booth (#5151) throughout the meeting from March 20-24.

“This clinical data includes positive safety, efficacy and cosmetic results from patients treated in the longest-running NMSC clinical trial of the Xoft System to date,” said Ken Ferry, CEO of iCAD. “Collectively, 848 patients are being followed in the three studies evaluating the Xoft System’s effectiveness for the treatment of non-melanoma skin cancer. As more long-term data from these studies become available, we believe it will drive increased adoption by physicians and greater interest from patients in this unique non-surgical treatment option. We are also pleased to showcase our new comprehensive solution at the AAD meeting, which is lowering the technological and logistical barriers for customers, helping more physicians adopt the Xoft System in their practices.”

The E-posters will be presented at the meeting in the Non-Melanoma Skin Cancer section at Center E- Poster Presentation Center 1 and will be available to view online at www.aad.org on Friday, March 20, 2015.

Electronic Brachytherapy for Non-Melanomatous Skin Cancer: Report of First 565 Lesions E-Poster #2027
Stephen Doggett, M.D., Aegis Oncology, LLC
Monday, March 23, 2015 from 11:50 a.m. to 11:55 a.m.

Electronic Brachytherapy for the Treatment of Non-Melanoma Skin Cancer: Results up to 4 Years E-Poster #2005
Ajay Bhatnagar, M.D., MBA, 21st Century Oncology of Arizona
Monday, March 23, 2015 from 11:55 a.m. to 12:00 p.m.

Initial Experience of Electronic Brachytherapy for the Treatment of 508 Non-melanoma Skin Cancer (NMSC) Lesions in 305 Patients
E-Poster # 2013
Robert Strimling, M.D., FAAD and Camtu Lee Jones
Monday, March 23, 2015 from 12:35 p.m. to 12:40 p.m.

“Study results suggest that electronic brachytherapy is an effective treatment for patients with non- melanoma skin cancer, with few recurrences or side effects and excellent cosmetic results,” said Ajay Bhatnagar, MD, MBA, medical director of 21st Century Oncology of Arizona. “The studies support the use of the Xoft System for patients with non-melanoma skin cancer who are not candidates for surgical excision or traditional radiation therapy.”

At the meeting, iCAD will also showcase its new comprehensive solution for clinical practices interested in implementing a skin electronic brachytherapy program. Comprised of the medical device, software, management services and support, Xoft Skin eBx offers a scalable and modular program that enables radiation oncology supervision with the necessary components to successfully incorporate a skin eBx program into any dermatology practice.

The Xoft System

The Xoft System is FDA cleared to treat cancer anywhere in the body, including skin, vaginal, endometrial, cervical, and early-stage breast cancer. It has been used to treat more than 10,000 NMSC patients to date.

About Xoft Axxent Electronic Brachytherapy System

The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.

About iCAD, Inc.

iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Contact:

For iCAD investor relations:

The Ruth Group
Zack Kubow, 646-536-7030 /7024
iCAD@theruthgroup.com

For iCAD media inquiries:

Berry & Company Public Relations, LLC
Jessica Burns, 212-253-8881
jburns@berrypr.com